Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

Next Previous
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risankizumab (Primary) ; Risankizumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ADVANCE
  • Sponsors AbbVie; AbbVie Germany

Most Recent Events

  • 28 Nov 2025 According to AbbVie Media Release, SKYRIZI (risankizumab), has received 2 consecutive positive reimbursement recommendations by Canada's Drug Agency (CDA-AMC), initially for Crohn's disease (CD) and now for ulcerative colitis (UC). For CD, this approval is supported by evidence from pivotal phase 3 clinical trials including MOTIVATE, ADVANCE, FORTIFY.
  • 17 Oct 2023 Results of a post-hoc analysis assessing EIM resolution in patients with moderate to severe Crohn's disease (CD) who received risankizuma using pooled data from ADVANCE, MOTIVATE and FORTIFY studies presented at the 31st United European Gastroenterology Week
  • 17 Oct 2023 Results assessing to conduct a placebo anchored matching-adjusted indirect comparison of endoscopic outcomes between upadacitinib and ustekinumab among patients with moderately to severely active CD from phase 3 UPA trials (NCT03105128, 03104413, 03105102) and UST endoscopy sub-studies (NCT01369329, 01369342, 01369355) from the phase 3 UNITI/IM-UNITI program, presented at the 31st United European Gastroenterology Week.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top